Delve Bio, a UCSF spin-out and pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, announced data underscoring the clinical impact of mNGS using Delve Detect to identify ...

BOSTON--(BUSINESS WIRE)--Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, in collaboration with the University of California, San Francisco (UCSF), today ...

BOSTON--(BUSINESS WIRE)--Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, in collaboration with the University of California, San Francisco (UCSF), today ...

Tevogen Bio announced up to $10 million in grant funding to enhance cancer and viral infection therapies and AI initiatives. Tevogen Bio, a clinical-stage biotech company focused on immunotherapy, ...

The development of VTP-300 in chronic Hepatitis B (CHB) and VTP-1000 in celiac disease will be prioritized. The pipeline prioritization is expected to result in a reduction in workforce of ...

Major Milestone for EVŌQ Nano's Biotech Arm Targeting Antibiotic-Resistant Bacterial Infections Linked to Cystic Fibrosis and Other Lung Diseases The inhaled therapeutic uses EVŌQ Nano's novel ...

Barinthus Bio says no significant improvement from VTP-200 was observed in the overall pooled results. Future development options for the VTP-200 program are being evaluated with ongoing analyses. 9 ...

Around the globe, fungal infections affect more than 1 billion people and account for several million deaths every year. They pose a particular problem in low- and middle-income countries, where ...

While most human papillomavirus (HPV) infections are cleared by the host immune system, persistent infection with high-risk HPV genotypes, particularly HPV16 and HPV18, can promote cervical cancer ...

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy ...